| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/30/2005 | CA2553542A1 Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad |
| 04/28/2005 | WO2005037928A2 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | WO2005037839A1 Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof |
| 04/28/2005 | WO2005037799A1 Compounds, compositions, and methods |
| 04/28/2005 | WO2005037286A1 Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
| 04/28/2005 | WO2005037198A2 Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors |
| 04/28/2005 | WO2005037197A2 Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors |
| 04/28/2005 | WO2005037052A2 Binding assay with labelled bispidine variant |
| 04/28/2005 | WO2004098634A3 Protein arginine n-methyltransferase 2 (prmt-2) |
| 04/28/2005 | WO2004075893A8 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker |
| 04/28/2005 | WO2004014844A3 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 04/28/2005 | WO2004014842A8 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 04/28/2005 | WO2004005262A8 New neuropeptide y y5 receptor antagonists |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 04/28/2005 | US20050090752 Method for evaluating and treating hypertension |
| 04/28/2005 | US20050090672 Intermediates for production of losartan; chloroformylation; hydroxylation; angiotensin II antagonists; hypertension |
| 04/28/2005 | US20050090669 Aminoalcohol derivatives as beta-3 adrenergic receptor agonists |
| 04/28/2005 | US20050090556 Method for treatment of external secretion disorders |
| 04/28/2005 | US20050090555 Compound for the treatment of metabolic disorders |
| 04/28/2005 | US20050090542 crystalline polymorphic dosage forms of anticholesterol agents; statins |
| 04/28/2005 | US20050090536 Substituted pyrrol-3-ylisoxazoles, e.g., N-benzyl-4-[4-(o-chlorophenyl)-5-isoxazolyl)pyrrole-2-carboxamide; treating diseases that are alleviated by a protein kinase inhibitor, particularly cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 04/28/2005 | US20050090532 Medicinal uses of dihydropyrazoles |
| 04/28/2005 | US20050090525 carboxymethylated N-(nitrogen group functionalized alkyl- carbonylhydrazido)- or carbonylaminomethylcarbonyl)- substituted; integrin inhibitors used for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumors, osteoporosis, infections and restenosis |
| 04/28/2005 | US20050090524 Novel adamantane derivatives |
| 04/28/2005 | US20050090519 1-Alkyl-4-(3-substitutedphenyl)piperidines |
| 04/28/2005 | US20050090516 Novel substituted imides |
| 04/28/2005 | US20050090513 Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090502 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents |
| 04/28/2005 | US20050090501 Heteroaryl-cyclic acetals |
| 04/28/2005 | US20050090493 Useful as anti-cancer agents; exhibit apoptotic effect in a warm-blooded animal such as man; for example, 2-{4-[3-(N,N-Dimethyl)amino-2-hydroxy-propoxy]anilino}-4-(2,4-difluoro-(N-cyanomethyl)anilino)pyrimidine |
| 04/28/2005 | US20050090491 2'-Methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/28/2005 | US20050090490 3-Substituted-4-pyrimidone derivatives |
| 04/28/2005 | US20050090487 Cardiovascular disorders; antiinflammatory agents |
| 04/28/2005 | US20050089984 Having a specific amino acid sequence, especially fused to a heterologous polypeptide; induces apoptosis |
| 04/28/2005 | US20050089970 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 04/28/2005 | US20050089938 For treatment of epilepsy, hypertension, angina pectoris, cerebral ischaemia, Parkinson's disease, insulin-dependent diabetes, and/or Lambert-Eaton myasthenic syndrome |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089897 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 04/28/2005 | US20050089871 G protein-related kinase mutants in essential hypertension |
| 04/28/2005 | US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders |
| 04/28/2005 | US20050089547 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/28/2005 | US20050089520 Antibody stimulating il-ira production |
| 04/28/2005 | US20050089495 Transdermal transport of compounds |
| 04/28/2005 | US20050087198 Method for systemic drug delivery through the nail |
| 04/28/2005 | CA2549579A1 Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
| 04/28/2005 | CA2543447A1 Antibody and use of the same |
| 04/28/2005 | CA2543406A1 Mutants of human chondromodulin-i (hchm-i) and uses thereof in inhibiting angiogenesis and bone resorption |
| 04/28/2005 | CA2542694A1 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | CA2542504A1 Lipids containing omega-3 and omega-6 fatty acids |
| 04/28/2005 | CA2542290A1 Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof |
| 04/27/2005 | EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei |
| 04/27/2005 | EP1526140A1 Novel potassium-dependent sodium-calcium exchanger |
| 04/27/2005 | EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators |
| 04/27/2005 | EP1526132A2 Substituted oxazolidinone derivatives and their use as factor xa inhibitors |
| 04/27/2005 | EP1525888A1 Angiogenically effective unit dose of FGF-2 and method of use |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525204A1 Phenylalanine enamide derivatives |
| 04/27/2005 | EP1525201A1 Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| 04/27/2005 | EP1525200A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 04/27/2005 | EP1525199A1 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 04/27/2005 | EP1525198A2 Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525194A1 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 04/27/2005 | EP1525193A2 Acylaminothiazole derivatives, preparation and therapeutic use thereof |
| 04/27/2005 | EP1525191A2 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives |
| 04/27/2005 | EP1525188A2 Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same |
| 04/27/2005 | EP1525177A1 Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
| 04/27/2005 | EP1524997A1 Stable liquid parenteral parecoxib formulation |
| 04/27/2005 | EP1524996A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 04/27/2005 | EP1524989A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 04/27/2005 | EP1524984A1 Myocardial perfusion imaging using a2a receptor agonists |
| 04/27/2005 | EP1524980A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 04/27/2005 | EP1524977A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/27/2005 | EP1524974A2 Transcription factor modulating compounds and methods of use thereof |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1358320A4 68730 and 69112 protein kinase molecules and uses therefor |
| 04/27/2005 | EP1261327B1 Adenosine receptor modulators |
| 04/27/2005 | EP1135153B1 Uses for eph receptor antagonists and agonists to treat vascular disorders |
| 04/27/2005 | EP1040098B1 Integrin receptor antagonists |
| 04/27/2005 | EP1011651B1 Method of treating diabetes and related disease states |
| 04/27/2005 | EP0994853B1 A monoether of probucol and methods for the inhibition of the expression of vcam-1 |
| 04/27/2005 | EP0942733B1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 04/27/2005 | EP0918515B1 USE OF INHIBITORS OF THE CELLULAR Na+ /H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS |
| 04/27/2005 | EP0906307B1 Substituted imidazoles having cytokine inhibitory activity |
| 04/27/2005 | CN1610751A Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof |
| 04/27/2005 | CN1610691A 2-O-(beta-D-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610671A Quinoline compounds with 5-HT-antagonistic properties for therapy |
| 04/27/2005 | CN1610669A Heteroaryl-substituted aminocyclohexane derivatives |
| 04/27/2005 | CN1610666A Benzamidine derivative |
| 04/27/2005 | CN1610661A Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 04/27/2005 | CN1610659A Carboxylic acid derivative |
| 04/27/2005 | CN1610548A Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
| 04/27/2005 | CN1610502A Surfactant protein for the prevention and diagnosis of pulmonary emphysema |
| 04/27/2005 | CN1609206A Crystal structure of oxidosqualene cyclase |
| 04/27/2005 | CN1609114A Notoginseng leaf total flavone and its prepn and application |
| 04/27/2005 | CN1609108A Prepn process of isosorbide mononitrate |
| 04/27/2005 | CN1609105A 1-methylolimidazole [1, 2-alpha] quinoxaline compound and its application |